A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-09-09) →
What happened
HEM Pharma updated a previously disclosed supply contract with access business group, now worth US$3.4M, about 35.48% of its recent annual revenue, running through Oct 2026.
For context, this single contract equals about 35.48% of the company's most recent annual revenue.
| Counterparty | access business group |
|---|---|
| Contract value | US$3.4M |
| vs. recent revenue | 35.48% |
| Through | Oct 2026 (from Jun 2026) |
| Filed | 2026-09-04, [Amended] Supply contract signed |
| Source | DART rcept 20260904900696 → open original filing |
Versions of this filing
- 2026-06-24Original
- 2026-09-04Amendment 1 (this page)
- 2026-09-09Amendment 2
Source: DART. Information only, not investment advice.